Breast Cancer
<ѻýҕl class="page-description"> ѻýҕl>More in Breast Cancer
Broad indication doubles the number of patients eligible for adjuvant CDK4/6 inhibition
Sep 17, 2024
Absolute difference of 4.9% at 5 years, including a benefit for patients who did not achieve pCR
Sep 17, 2024
Second-line T-DXd best option in patients with and without intracranial activity, experts says
Sep 14, 2024
But benefit in modeling study accompanied by more false-positive biopsy recommendations
Aug 26, 2024
1.00
CME Credits